Weill Cornell Medicine Participates in $26.5m Collaborative Study to Eliminate HIV for Good

Weill Cornell Medicine Participates in $26.5m Collaborative Study to Eliminate HIV for Good

A new research collaborative has been formed to overcome the present-day challenges in combating HIV, a disease that has— thanks to the advancement of medical knowledge, treatments, and proactive care—transitioned from what was a deadly and mysterious virus to one that can be managed and controlled with daily drugs. While previous attempts to eradicate this pathogen have failed, that isn’t stopping a new, financed group from trying again. Now, with a $26.5-million grant from the National Institutes of Health (NIH), a multi-disciplinary group of researchers from institutions around the world is trying a completely new strategy for curing HIV. Known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, it will be led by researchers at Gladstone Institutes, Scripps Research, and Weill Cornell Medicine. Their approach, which aims to silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.

TrialSite shares recent important news from Weill Cornell Medicine, the preeminent New York State-based biomedical research center and medical school of Cornell University, a priva...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee